5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Cancer Type, Drug Type, and Geography.
Fastest Growing Market:
The solid tumor therapeutics market is expected to register a CAGR of 15% during the forecast period. The major factors that are responsible for the growth of this market include new product approvals in ovarian, pancreatic, and prostate cancers, and increasing government initiatives for cancer awareness. In addition, the other crucial driving factor is the increasing incidence of cancer. For instance, cancer has a significant impact on societies across the world. The most common cancers in 2016 were breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer.
Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could prevent this trend and prevent as many as one-third of all cancers, worldwide. The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths, due to cancer in 2016, in the United States. Hence, the increasing number of patients is expected to drive the market during the forecast period.
However, factors, such as stringent regulatory reforms and price erosion due to generic competition may hinder the growth of this market.
Solid tumor therapeutics are pharmaceuticals that specifically treat various cancers, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas.
|By Cancer Type|
|Other Cancer Types|
|By Drug Type|
|Other Drug Types|
Report scope can be customized per your requirements. Click here.
Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. More than 80% of all cancers are caused by solid tumors that grow as a mass of cells in a particular organ, tissue or gland. According to the American Cancer Society, as of 2018, it is estimated that approximately 268,670 new breast cancer cases are expected in the United States. And even several major companies are investing in the development of new treatments for cancers. For example, Ibrance (palbociclib) by Pfizer is for the treatment of ER-positive, HER2-negative breast cancer and has been approved in February 2015. A trial of the use of two drugs in combination found that tumors were completely cleared in 11% of patients with HER2-positive breast cancer and were reduced to a “minimal” size in a further 17%. Nearly 90% saw a reduction in the number of cancer cells. Hence, with the entry of new drugs the segment is expected to continue its lead as the number of cases is also helping in the growth.
To understand key trends, Download Sample Report
North America currently dominates the market for solid tumor therapeutics, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to increasing incidence rates of cancer and increasing awareness among people, and the presence of developed healthcare infrastructure are propelling the growth of the market in the forecast period.
To understand geography trends, Download Sample Report.
The solid tumor therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need for cancer treatment and increasing prevalence of cancer. However, the entry of a few smaller players in the market is excepted and they may hold a substantial share. Some of the major players of the market are Abbott Laboratories Inc., Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Cancer
4.2.2 New Product Approvals in Ovarian, Pancreatic, and Prostate Cancers
4.2.3 Increasing Government Initiatives for Cancer Awareness
4.3 Market Restraints
4.3.1 Stringent Regulatory Reforms
4.3.2 Price Erosion due to Generic Competition
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Colorectal Cancer
5.1.4 Prostate Cancer
5.1.5 Cervical Cancer
5.1.6 Other Cancer Types
5.2 By Drug Type
5.2.10 Other Drug Types
5.3.1 North America
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 Amgen Inc.
6.1.3 AstraZeneca PLC
6.1.4 Baxter International Inc.
6.1.5 Biogen Inc.
6.1.6 Boehringer Ingelheim GmbH
6.1.7 Bristol-Myers Squibb Company
6.1.8 Eli Lilly and Company
6.1.9 F. Hoffmann-La Roche AG
6.1.10 GlaxoSmithKline PLC
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments